n-3 Fatty acids combined with flavan-3-ols prevent steatosis and liver injury in a murine model of NAFLD

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1864, Issue 1, 2018, Pages 69-78

  Vauzour, David ^a   Rodriguez Ramiro, Ildefonso ^a   Rushbrook, Simon ^b   Ipharraguerre, Ignacio R ^c   Bevan, Damon ^a,d   Davies, Susan ^e   Tejera, Noemi ^a   Mena, Pedro ^f   de Pascual Teresa, Sonia ^g   Del Rio, Daniele ^f   Gavrilovic, Jelena ^d   Minihane, Anne Marie ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF PARMA   (Italy)

^g INSTITUTE OF FOOD SCIENCE   (Spain)

Author keywords

Bile acids; Fish oil; Flavonoids; NASH; Srebp 1c

Indexed keywords

BILE ACID; CD36 ANTIGEN; FARNESOID X RECEPTOR; FATTY ACID BINDING PROTEIN 4; FISH OIL; FLAVAN 3 OL; FLAVAN DERIVATIVE; FRUCTOSE; GLUCOSE; INSULIN; LIVER PROTECTIVE AGENT; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG; FLAVAN-3-OL; FLAVONOID;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CARBOHYDRATE DIET; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL FATTY LIVER; EXPERIMENTAL LIVER INJURY; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; LIPOGENESIS; LIVER CELL; LIVER PROTECTION; MALE; MOUSE; MURINE MODEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CELL PROTECTION; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; FATTY LIVER; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FATTY ACIDS, OMEGA-3; FATTY LIVER; FLAVONOIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85031713671     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2017.10.002     Document Type: Article

References (53)

1. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84 (Baltimore, MD).
2. Sattar, N., Forrest, E., Preiss, D., Non-alcoholic fatty liver disease. BMJ, 349, 2014, g4596 (Clinical research ed.).
3. Wree, A., Broderick, L., Canbay, A., Hoffman, H.M., Feldstein, A.E., From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 627–636.
4. Bhatia, L.S., Curzen, N.P., Calder, P.C., Byrne, C.D., Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur. Heart J. 33 (2012), 1190–1200.
5. Day, C.P., James, O.F., Steatohepatitis: a tale of two “hits”?. Gastroenterology 114 (1998), 842–845.
6. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., Chalasani, N., Dasarathy, S., Diehl, A.M., Hameed, B., Kowdley, K.V., McCullough, A., Terrault, N., Clark, J.M., Tonascia, J., Brunt, E.M., Kleiner, D.E., Doo, E., Farnesoid, X., nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965 (London, England).
7. Marsman, H.A., Heger, M., Kloek, J.J., Nienhuis, S.L., van Werven, J.R., Nederveen, A.J., Ten Kate, F.J., Stoker, J., van Gulik, T.M., Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) H-magnetic resonance spectroscopy in a rat model. J. Gastroenterol. Hepatol. 26 (2011), 356–363.
8. Di Minno, M.N., Russolillo, A., Lupoli, R., Ambrosino, P., Di Minno, A., Tarantino, G., Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J. Gastroenterol. 18 (2012), 5839–5847.
9. Parker, H.M., Johnson, N.A., Burdon, C.A., Cohn, J.S., O'Connor, H.T., George, J., Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol. 56 (2012), 944–951.
10. Scorletti, E., Bhatia, L., McCormick, K.G., Clough, G.F., Nash, K., Hodson, L., Moyses, H.E., Calder, P.C., Byrne, C.D., Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the *WELCOME study. Hepatology 60 (2014), 1211–1221.
11. Rodriguez-Ramiro, I., Vauzour, D., Minihane, A.M., Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms. Proc. Nutr. Soc. 75 (2016), 47–60.
12. Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. FASEB J. 22 (2008), 659–661.
13. Sansone, R., Ottaviani, J.I., Rodriguez-Mateos, A., Heinen, Y., Noske, D., Spencer, J.P., Crozier, A., Merx, M.W., Kelm, M., Schroeter, H., Heiss, C., Methylxanthines enhance the effects of cocoa flavanols on cardiovascular function: randomized, double-masked controlled studies. Am. J. Clin. Nutr. 105 (2017), 352–360.
14. Minihane, A.M., Fish oil omega-3 fatty acids and cardio-metabolic health, alone or with statins. Eur. J. Clin. Nutr. 67 (2013), 536–540.
15. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
16. Chowdhry, S., Nazmy, M.H., Meakin, P.J., Dinkova-Kostova, A.T., Walsh, S.V., Tsujita, T., Dillon, J.F., Ashford, M.L., Hayes, J.D., Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic. Biol. Med. 48 (2010), 357–371.
17. Brunt, E.M., Kleiner, D.E., Wilson, L.A., Belt, P., Neuschwander-Tetri, B.A., Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53 (2011), 810–820 (Baltimore, Md.).
18. Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y.C., Torbenson, M.S., Unalp-Arida, A., Yeh, M., McCullough, A.J., Sanyal, A.J., Nonalcoholic Steatohepatitis, N., Clinical research, design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321 (Baltimore, Md.).
19. Vauzour, D., Tejera, N., O'Neill, C., Booz, V., Jude, B., Wolf, I.M., Rigby, N., Silvan, J.M., Curtis, P.J., Cassidy, A., de Pascual, S., Teresa, G., Rimbach, A.M., Minihane, anthocyanins do not influence long-chain n-3 fatty acid status: studies in cells, rodents and humans. J. Nutr. Biochem. 26 (2015), 211–218.
20. Yamashita, Y., Okabe, M., Natsume, M., Ashida, H., Prevention mechanisms of glucose intolerance and obesity by cacao liquor procyanidin extract in high-fat diet-fed C57BL/6 mice. Arch. Biochem. Biophys. 527 (2012), 95–104.
21. Murray, M.Y., Birkland, T.P., Howe, J.D., Rowan, A.D., Fidock, M., Parks, W.C., Gavrilovic, J., Macrophage migration and invasion is regulated by MMP10 expression. PLoS One, 8, 2013, e63555.
22. Bresciani, L., Calani, L., Bocchi, L., Delucchi, F., Savi, M., Ray, S., Brighenti, F., Stilli, D., Del Rio, D., Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. Nutr. Metab. Cardiovasc. Dis. 24 (2014), 408–415.
23. Robbins, R.J., Leonczak, J., Li, J., Johnson, J.C., Collins, T., Kwik-Uribe, C., Schmitz, H.H., Flavanol and procyanidin content (by degree of polymerization 1–10) of chocolate, cocoa liquors, cocoa powders, and cocoa extracts: first action 2012.24. J. AOAC Int. 96 (2013), 705–711.
24. Kreiser, W.R., Martin, R.A. Jr., High pressure liquid chromatographic determination of theobromine and caffeine in cocoa and chocolate products: collaborative study. J. Assoc. Off. Anal. Chem. 63 (1980), 591–594.
25. Rodriguez-Mateos, A., Vauzour, D., Krueger, C.G., Shanmuganayagam, D., Reed, J., Calani, L., Mena, P., Del Rio, D., Crozier, A., Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. Arch. Toxicol. 88 (2014), 1803–1853.
26. P.I. RAMP/12341, Living well for longer: national support for local action to reduce premature avoidable. Mortality, 2014.
27. Argo, C.K., Caldwell, S.H., Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis. 13 (2009), 511–531.
28. Gu, Y., Yu, S., Lambert, J.D., Dietary cocoa ameliorates obesity-related inflammation in high fat-fed mice. Eur. J. Nutr. 53 (2014), 149–158.
29. Matsui, N., Ito, R., Nishimura, E., Yoshikawa, M., Kato, M., Kamei, M., Shibata, H., Matsumoto, I., Abe, K., Hashizume, S., Ingested cocoa can prevent high-fat diet-induced obesity by regulating the expression of genes for fatty acid metabolism. Nutrition 21 (2005), 594–601.
30. Gu, Y., Hurst, W.J., Stuart, D.A., Lambert, J.D., Inhibition of key digestive enzymes by cocoa extracts and procyanidins. J. Agric. Food Chem. 59 (2011), 5305–5311.
31. Grassi, D., Lippi, C., Necozione, S., Desideri, G., Ferri, C., Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am. J. Clin. Nutr. 81 (2005), 611–614.
32. Greenberg, J.A., Axen, K.V., Schnoll, R., Boozer, C.N., Coffee, tea and diabetes: the role of weight loss and caffeine. Int. J. Obes. 29 (2005), 1121–1129.
33. Zheng, G., Sayama, K., Okubo, T., Juneja, L.R., Oguni, I., Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. In Vivo 18 (2004), 55–62.
34. Ito, Y., Ichikawa, T., Morohoshi, Y., Nakamura, T., Saegusa, Y., Ishihara, K., Effect of tea catechins on body fat accumulation in rats fed a normal diet. Biomed. Res. 29 (2008), 27–32 (Tokyo, Japan).
35. Dawson, P.A., Karpen, S.J., Intestinal transport and metabolism of bile acids. J. Lipid Res. 56 (2015), 1085–1099.
36. Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R.G., Krausz, K.W., Cai, J., Qi, Y., Fang, Z.Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S.G., Albert, I., Patterson, A.D., Gonzalez, F.J., Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125 (2015), 386–402.
37. Sayin, S.I., Wahlstrom, A., Felin, J., Jantti, S., Marschall, H.U., Bamberg, K., Angelin, B., Hyotylainen, T., Oresic, M., Backhed, F., Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17 (2013), 225–235.
38. Mueller, M., Thorell, A., Claudel, T., Jha, P., Koefeler, H., Lackner, C., Hoesel, B., Fauler, G., Stojakovic, T., Einarsson, C., Marschall, H.U., Trauner, M., Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J. Hepatol. 62 (2015), 1398–1404.
39. Gonzalez, F.J., Jiang, C., Xie, C., Patterson, A.D., Intestinal Farnesoid, X., Receptor signaling modulates metabolic disease. Dig. Dis. 35 (2017), 178–184.
40. Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K.W., Shi, J., Brocker, C.N., Desai, D., Amin, S.G., Bisson, W.H., Liu, Y., Gavrilova, O., Patterson, A.D., Gonzalez, F.J., Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun., 6, 2015, 10166.
41. Akinrotimi, O., Riessen, R., VanDuyne, P., Park, J.E., Lee, Y.K., Wong, L.J., Zavacki, A.M., Schoonjans, K., Anakk, S., Shp deletion prevents hepatic steatosis and when combined with Fxr loss protects against type 2 diabetes. Hepatology, 2017, 10.1002/hep.29305 (Baltimore, Md.).
42. Li, T., Owsley, E., Matozel, M., Hsu, P., Novak, C.M., Chiang, J.Y., Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52 (2010), 678–690 (BaltimoreMD).
43. Park, H.K., Ahima, R.S., Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism 64 (2015), 24–34.
44. Polyzos, S.A., Aronis, K.N., Kountouras, J., Raptis, D.D., Vasiloglou, M.F., Mantzoros, C.S., Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 59 (2016), 30–43.
45. Sainz, N., Barrenetxe, J., Moreno-Aliaga, M.J., Martinez, J.A., Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism 64 (2015), 35–46.
46. Martin, S.S., Qasim, A., Reilly, M.P., Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J. Am. Coll. Cardiol. 52 (2008), 1201–1210.
47. Park, H.J., Jung, U.J., Lee, M.K., Cho, S.J., Jung, H.K., Hong, J.H., Park, Y.B., Kim, S.R., Shim, S., Jung, J., Choi, M.S., Modulation of lipid metabolism by polyphenol-rich grape skin extract improves liver steatosis and adiposity in high fat fed mice. Mol. Nutr. Food Res. 57 (2013), 360–364.
48. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005), 1343–1351.
49. Masterton, G.S., Plevris, J.N., Hayes, P.C., Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 31 (2010), 679–692.
50. Scorletti, E., Byrne, C.D., Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu. Rev. Nutr. 33 (2013), 231–248.
51. Wang, Z., Dou, X., Li, S., Zhang, X., Sun, X., Zhou, Z., Song, Z., Nuclear factor (erythroid-derived 2)-like 2 activation-induced hepatic very-low-density lipoprotein receptor overexpression in response to oxidative stress contributes to alcoholic liver disease in mice. Hepatology 59 (2014), 1381–1392 (Baltimore, Md.).
52. de Aguiar Vallim, T.Q., Tarling, E.J., Edwards, P.A., Pleiotropic roles of bile acids in metabolism. Cell Metab. 17 (2013), 657–669.
53. Giunta, B., Hou, H., Zhu, Y., Salemi, J., Ruscin, A., Shytle, R.D., Tan, J., Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice. Neurosci. Lett. 471 (2010), 134–138.